GO:0032913 negative regulation of transforming growth factor beta3 production: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032913 describes any process that stops, prevents, or reduces the production of transforming growth factor beta3 (TGF-beta3).
• TGF-beta3 is a secreted cytokine involved in extracellular matrix regulation, chondrogenesis, and tissue repair [2, 8].
• Negative regulation of TGF-beta3 production is observed in response to growth factors, inflammatory signals, and pharmacological agents such as NSAIDs [2, 5].
• Dysregulated TGF-beta3 production is linked to fibrosis, impaired bone healing, and cancer progression [2, 6].
• Key regulatory nodes include receptor tyrosine kinase signaling, Smad3 activity, and inflammatory cytokines like IL-1beta [1, 5, 8].
• CRISPR-based models (knockout, knock-in, overexpression) enable causal dissection of TGF-beta3 regulatory pathways.
Description
Transforming growth factor beta3 (TGF-beta3) is a member of the TGF-beta superfamily of secreted cytokines that regulate cell proliferation, differentiation, and extracellular matrix production [1, 2]. The production of TGF-beta3 is tightly controlled at transcriptional and post-transcriptional levels, and its dysregulation contributes to a range of pathological conditions including fibrosis, impaired bone healing, and cancer [2, 6]. GO:0032913, negative regulation of transforming growth factor beta3 production, captures the biological processes that reduce the frequency, rate, or extent of TGF-beta3 synthesis and secretion. Understanding this regulatory node is critical for researchers investigating tissue repair, chondrogenesis, and inflammatory diseases [2, 8]. This article integrates authoritative QuickGO annotation with published literature to provide a research-grade overview of the mechanisms, genes, and experimental models relevant to GO:0032913.
negative regulation of transforming growth factor beta3 production At A Glance
| GO ID | GO:0032913 |
|---|---|
| GO term | negative regulation of transforming growth factor beta3 production |
| Ontology | biological_process |
| Synonym | down regulation of transforming growth factor-beta3 production; inhibition of transforming growth factor-beta3 production; negative regulation of TGF-B3 production; negative regulation of TGFB3 production |
| Major function | Reduces the synthesis or secretion of TGF-beta3, a cytokine involved in extracellular matrix regulation and chondrogenesis |
| Related processes | Regulation of TGF-beta3 production; TGF-beta receptor signaling; chondrocyte differentiation; bone healing |
| Cellular context | Secreted cytokine; produced by chondrocytes, fibroblasts, epithelial cells, and immune cells |
| Disease relevance | Fibrosis, impaired bone healing, cancer progression, autoimmune conditions |
What Is GO:0032913?
GO:0032913 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta3. It encompasses molecular events that downregulate TGF-beta3 gene expression, mRNA stability, translation, or secretion, and is distinct from negative regulation of other TGF-beta isoforms such as TGF-beta1 or TGF-beta2.
Why Is negative regulation of transforming growth factor beta3 production Important in Cell Biology?
GO:0032913 is important because TGF-beta3 plays a central role in skeletal development, wound healing, and immune regulation, and its overproduction or insufficient downregulation is associated with pathological fibrosis and impaired tissue repair [2, 8]. Pharmacological inhibition of TGF-beta3 production by NSAIDs has been shown to impair bone healing, highlighting the clinical significance of this regulatory process. Moreover, decreased TGF-beta3 expression is observed in cervical precancer, suggesting a role in epithelial carcinogenesis. Thus, understanding the mechanisms that negatively regulate TGF-beta3 production can inform therapeutic strategies for fibrosis, bone regeneration, and cancer.
• TGF-beta3 is essential for chondrogenic differentiation and endochondral ossification [2, 8].
• Negative regulation of TGF-beta3 production by NSAIDs contributes to impaired bone healing.
• TGF-beta3 downregulation is observed in HPV 16-positive cervical precancer, linking it to cancer progression.
• Receptor tyrosine kinase-activating growth factors negatively regulate collagen genes and may influence TGF-beta3 production.
• Inflammatory cytokines such as IL-1beta suppress GDF-5, which enhances TGF-beta3-mediated chondrogenesis.
• Smad3 activity is required for basal collagen production and may intersect with TGF-beta3 regulatory networks.
• TGF-beta3 is a potential therapeutic target in fibrosis and osteoarthritis [2, 8].
• CRISPR screening can identify novel regulators of TGF-beta3 production.
• Understanding GO:0032913 aids in designing interventions for bone and cartilage disorders.
• TGF-beta3 regulation is relevant to autoimmune diseases such as juvenile arthritis.
What Happens During negative regulation of transforming growth factor beta3 production?
Transcriptional repression of TGFB3
In simple terms: The cell reduces the reading of the TGFB3 gene into messenger RNA.
Negative regulation of TGF-beta3 production can occur at the transcriptional level, where transcription factors or signaling pathways repress the TGFB3 promoter. For example, receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats, suggesting a broader suppression of matrix-related genes including TGFB3. In juvenile arthritis, autoimmunity to type II collagen may alter TGF-beta3 expression in joint tissues.
Post-transcriptional and translational control
In simple terms: Even if mRNA is made, the cell can block its translation into protein or degrade it.
MicroRNAs and RNA-binding proteins can target TGFB3 mRNA for degradation or inhibit its translation. In HPV 16-positive cervical precancer, decreased synthesis and expression of TGF-beta1, beta2, and beta3 were observed by quantitative RT-PCR and immunocytochemistry, indicating post-transcriptional downregulation. NSAIDs such as ibuprofen and indomethacin downregulate TGF-beta3 expression during endochondral ossification, likely through post-transcriptional mechanisms.
Inhibition of secretion and processing
In simple terms: The cell may produce the protein but fail to release it outside.
TGF-beta3 is secreted as a latent complex that requires activation. Negative regulation can occur by preventing the processing or secretion of the latent complex. In rheumatoid fibroblast-like synoviocytes, IL-1beta suppresses GDF-5, which enhances TGF-beta3-mediated chondrogenic differentiation, suggesting that inflammatory signals can indirectly reduce TGF-beta3 bioavailability. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity, indicating that Smad3-dependent pathways may modulate TGF-beta3 production.
Feedback loops and signaling crosstalk
In simple terms: Signals from other pathways can turn down TGF-beta3 production.
Negative regulation of TGF-beta3 production is often part of feedback loops. For instance, TGF-beta itself can induce negative regulators such as Smad7, which may reduce TGF-beta3 production. In osteoclast differentiation, (+)-Vitisin A inhibits TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation, potentially affecting TGF-beta3 production in bone. Additionally, myostatin antibody administration in broilers altered muscle mass, suggesting crosstalk between TGF-beta family members.
Key Genes Involved in GO:0032913 negative regulation of transforming growth factor beta3 production
The following genes and proteins are experimentally implicated in the regulation of TGF-beta3 production or its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB3 | Encodes TGF-beta3 cytokine | Target for negative regulation; mutations affect palatogenesis and bone healing [2, 6] |
| SMAD3 | TGF-beta signaling mediator | Required for basal collagen production; may modulate TGF-beta3 feedback |
| SMAD7 | Inhibitory Smad | Negative feedback regulator of TGF-beta signaling; potential repressor of TGFB3 |
| IL1B | Pro-inflammatory cytokine | Suppresses GDF-5 and indirectly reduces TGF-beta3-mediated chondrogenesis |
| GDF5 | Growth differentiation factor 5 | Enhances TGF-beta3-mediated chondrogenic differentiation; suppressed by IL-1beta |
| TRAF6 | E3 ubiquitin ligase | Involved in NFATc1 activation; inhibition affects osteoclastogenesis and possibly TGF-beta3 |
| NFATC1 | Transcription factor | Downstream of TRAF6; regulates osteoclast differentiation and bone remodeling |
| SP1 | Transcription factor | Required for CCL18-stimulated collagen production; may influence TGF-beta3 |
| CCL18 | Chemokine | Stimulates collagen production in lung fibroblasts via Sp1 and Smad3 |
| COL2A1 | Type II collagen | Autoantigen in juvenile arthritis; linked to TGF-beta3 dysregulation |
| COL1A1 | Type I collagen | Negatively regulated by TGF-beta and RTK growth factors in hypertension |
| MSTN | Myostatin | TGF-beta family member; antibody effects on muscle mass suggest crosstalk |
| HPV16 E6/E7 | Viral oncoproteins | Associated with decreased TGF-beta1/2/3 expression in cervical precancer |
| PTGS2 | Cyclooxygenase-2 | Target of NSAIDs; inhibition downregulates TGF-beta3 during bone healing |
| RUNX2 | Osteoblast transcription factor | Master regulator of osteogenesis; may interact with TGF-beta3 signaling |
| SOX9 | Chondrogenic transcription factor | Essential for chondrocyte differentiation; TGF-beta3 enhances SOX9 activity |
| ACAN | Aggrecan | Cartilage proteoglycan; TGF-beta3 promotes its expression |
| MMP13 | Matrix metalloproteinase 13 | Degrades cartilage; TGF-beta3 may regulate its expression |
How Is negative regulation of transforming growth factor beta3 production Regulated?
The negative regulation of TGF-beta3 production is controlled by multiple signaling pathways. Receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats, suggesting a role in suppressing matrix-related genes including TGFB3. NSAIDs inhibit bone healing through downregulation of TGF-beta3 expression during endochondral ossification, indicating that prostaglandin synthesis pathways regulate TGF-beta3 production. Inflammatory cytokines such as IL-1beta suppress GDF-5, which enhances TGF-beta3-mediated chondrogenic differentiation, thereby indirectly reducing TGF-beta3 activity. Additionally, CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity, implicating these transcription factors in TGF-beta3 regulation.
negative regulation of transforming growth factor beta3 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB3 | Impaired bone healing, cervical precancer | TGFB3 knockout chondrocytes; NSAID-treated osteoblasts [2, 6] |
| IL1B | Rheumatoid arthritis, chondrogenic suppression | IL1B overexpression in synoviocytes; GDF5 rescue |
| SMAD3 | Fibrosis, collagen production | SMAD3 knockout lung fibroblasts; CCL18 stimulation |
| TRAF6 | Osteoclast differentiation, bone remodeling | TRAF6 knockout osteoclasts; (+)-Vitisin A treatment |
| COL2A1 | Juvenile arthritis, autoimmunity | COL2A1 knock-in mice; T cell autoimmunity assays |
Impaired bone healing and fracture repair
NSAIDs are commonly used for pain management but can impair bone healing. Pountos et al. demonstrated that NSAIDs inhibit bone healing through the downregulation of TGF-beta3 expression during endochondral ossification. This suggests that negative regulation of TGF-beta3 production by NSAIDs contributes to delayed fracture repair. Experimental models using CRISPR knockout of TGFB3 or its regulators could elucidate the precise mechanisms.
Cervical precancer and HPV infection
El-Sherif et al. found decreased synthesis and expression of TGF-beta1, beta2, and beta3 in epithelium of HPV 16-positive cervical precancer using microdissection, quantitative RT-PCR, and immunocytochemistry. This indicates that negative regulation of TGF-beta3 production may be a feature of early cervical carcinogenesis, potentially contributing to immune evasion or altered epithelial differentiation.
Juvenile arthritis and autoimmunity
Myers et al. reported that juvenile arthritis is associated with autoimmunity to type II collagen. Although the direct link to TGF-beta3 is not fully established, TGF-beta3 is known to modulate immune responses and cartilage homeostasis, and its negative regulation could exacerbate autoimmune joint damage. Further studies using CRISPR models could clarify this relationship.
Rheumatoid arthritis and chondrogenic differentiation
Liu et al. showed that GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes. This suggests that inflammatory signals in rheumatoid arthritis may negatively regulate TGF-beta3 production or activity, impairing cartilage repair. Targeting this pathway could be therapeutically beneficial.
From negative regulation of transforming growth factor beta3 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a candidate gene increase TGF-beta3 production? | CRISPR knockout in chondrocytes or fibroblasts |
| Does a specific point mutation in TGFB3 affect its secretion? | CRISPR point mutation knock-in in HEK293 or primary cells |
| Can a tagged TGF-beta3 reporter track production in real time? | Knock-in of fluorescent tag at TGFB3 locus |
| Does overexpression of a negative regulator reduce TGF-beta3 levels? | CRISPR activation (CRISPRa) or lentiviral overexpression |
| Which genes regulate TGF-beta3 production in a genome-wide screen? | CRISPR library screening with TGF-beta3 ELISA readout |
| Does NSAID treatment alter TGF-beta3 production in vivo? | Mouse fracture model with NSAID administration and TGFB3 knockout |
How to Study the negative regulation of transforming growth factor beta3 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| qRT-PCR | TGFB3 mRNA levels | Validation of CRISPR knockout or overexpression |
| ELISA | Secreted TGF-beta3 protein | Quantification in conditioned media |
| Immunocytochemistry | TGF-beta3 protein localization | Tissue sections from precancer or arthritis |
| CRISPR knockout screen | Genes affecting TGF-beta3 production | Genome-wide discovery of regulators |
| Proteomics | Secretome composition | Identifying secreted factors in fibrosis |
| Western blot | TGF-beta3 and signaling proteins | Pathway analysis in chondrocytes |
| Reporter assays | TGFB3 promoter activity | Transcriptional regulation studies |
| In vivo fracture model | Bone healing and TGF-beta3 expression | NSAID effects on bone repair |
Quantitative RT-PCR and immunocytochemistry
To measure TGF-beta3 production, researchers can use quantitative RT-PCR to assess TGFB3 mRNA levels and immunocytochemistry or ELISA to quantify protein. El-Sherif et al. used microdissection, quantitative RT-PCR, and immunocytochemistry to demonstrate decreased TGF-beta1, beta2, and beta3 in cervical precancer. These methods are suitable for validating CRISPR knockout or overexpression effects.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify novel regulators of TGF-beta3 production. By coupling TGF-beta3 ELISA or a reporter system to CRISPR libraries, researchers can discover genes whose loss or gain alters TGF-beta3 levels. This approach is powerful for uncovering pathways like those involving TRAF6 or Smad3 [5, 7].
Proteomics and secretome analysis
Mass spectrometry-based proteomics can quantify TGF-beta3 in conditioned media. This method is useful for studying post-transcriptional and secretion-level regulation. For example, NSAID-treated chondrocytes showed reduced TGF-beta3 expression during endochondral ossification. Secretome analysis can reveal whether negative regulation occurs at secretion or synthesis.
In vivo models of bone healing and fibrosis
Animal models such as rat fracture healing or bleomycin-induced lung fibrosis can be used to study negative regulation of TGF-beta3 production in a physiological context. Bray et al. used hypertensive rats to study TGF-beta and receptor tyrosine kinase regulation of collagen genes. These models allow assessment of TGF-beta3 dynamics and therapeutic interventions.
How CRISPR Can Be Used to Study GO:0032913 negative regulation of transforming growth factor beta3 production
Knockout
CRISPR knockout of TGFB3 or its regulators can be used to determine whether a gene is necessary for negative regulation of TGF-beta3 production. For example, knocking out SMAD3 in fibroblasts would test its role in basal collagen production and TGF-beta3 regulation. Similarly, TRAF6 knockout in osteoclasts can reveal its impact on TGF-beta3-mediated signaling.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid changes in TGFB3 or its regulatory proteins to dissect functional domains. For instance, mutating phosphorylation sites in Smad3 could reveal how it modulates TGF-beta3 production. Point mutations in the TGFB3 prodomain could affect its secretion and latency.
Knock-in
Knock-in of a fluorescent tag (e.g., GFP) at the TGFB3 locus allows real-time tracking of TGF-beta3 production in live cells. This approach can be combined with CRISPR screening to identify regulators that alter TGF-beta3 levels. Tagged knock-in models are also useful for studying secretion dynamics.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can be used to test whether a candidate gene negatively regulates TGF-beta3 production. Overexpressing SMAD7, an inhibitory Smad, would be expected to reduce TGF-beta3 levels. Conversely, overexpressing GDF5 could enhance TGF-beta3-mediated chondrogenesis.
How EDITGENE Supports negative regulation of transforming growth factor beta3 production Research
Researchers studying negative regulation of transforming growth factor beta3 production-related genes often need to determine whether a candidate gene is causally involved in reducing TGF-beta3 levels or whether it is merely correlated. EDITGENE provides a comprehensive suite of CRISPR services to enable such causal studies, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of transforming growth factor beta3 production research.
Frequently Asked Questions About negative regulation of transforming growth factor beta3 production
What is GO:0032913?
GO:0032913 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta3.
What genes are involved in negative regulation of TGF-beta3 production?
Genes such as TGFB3, SMAD3, SMAD7, IL1B, GDF5, TRAF6, and SP1 have been implicated in regulating TGF-beta3 production or its downstream effects [1, 5, 7, 8].
How do NSAIDs affect TGF-beta3 production?
NSAIDs inhibit bone healing through the downregulation of TGF-beta3 expression during endochondral ossification.
Is TGF-beta3 production decreased in cancer?
Yes, decreased synthesis and expression of TGF-beta1, beta2, and beta3 have been observed in HPV 16-positive cervical precancer.
What is the role of Smad3 in TGF-beta3 regulation?
Basal Smad3 activity is required for CCL18-stimulated upregulation of collagen production in lung fibroblasts, suggesting a role in TGF-beta3 regulatory networks.
How can I study negative regulation of TGF-beta3 production using CRISPR?
CRISPR knockout, point mutation knock-in, tagged knock-in, and overexpression models can be used to dissect causal roles of candidate genes.
What diseases are associated with dysregulated TGF-beta3 production?
Impaired bone healing, cervical precancer, juvenile arthritis, and rheumatoid arthritis have been linked to altered TGF-beta3 production [2, 4, 6, 8].
What methods measure TGF-beta3 production?
qRT-PCR, ELISA, immunocytochemistry, Western blot, and proteomics are commonly used to quantify TGF-beta3 mRNA and protein [2, 6].
Can CRISPR screening identify new regulators of TGF-beta3?
Yes, genome-wide CRISPR screens coupled with TGF-beta3 readouts can discover novel regulators.
What cell types produce TGF-beta3?
TGF-beta3 is produced by chondrocytes, fibroblasts, epithelial cells, and immune cells, among others [2, 6, 8].
Conclusion
GO:0032913, negative regulation of transforming growth factor beta3 production, is a critical biological process that controls the availability of a key cytokine involved in skeletal development, tissue repair, and immune regulation. Dysregulation of this process contributes to impaired bone healing, fibrosis, and cancer progression [2, 6]. Understanding the molecular mechanisms and identifying the genes that negatively regulate TGF-beta3 production can inform therapeutic strategies. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, provide powerful tools to dissect these pathways. EDITGENE offers comprehensive services to support such research, from custom cell line generation to library screening and bioinformatics.
References
- 1. Bray P et al.. 1998. Transforming growth factor-beta and receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats.. Hypertension 31(4):986-94 PMID: 9535425
- 2. Pountos I et al.. 2021. NSAIDs inhibit bone healing through the downregulation of TGF-β3 expression during endochondral ossification.. Injury 52(6):1294-1299 PMID: 33472741
- 3. Kim YS et al.. 2006. Production of a monoclonal anti-myostatin antibody and the effects of in ovo administration of the antibody on posthatch broiler growth and muscle mass.. Poult Sci 85(6):1062-71 PMID: 16776476
- 4. Myers LK et al.. 2001. Juvenile arthritis and autoimmunity to type II collagen.. Arthritis Rheum 44(8):1775-81 PMID: 11508428
- 5. Luzina IG et al.. 2006. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity.. J Cell Physiol 206(1):221-8 PMID: 16021625
- 6. El-Sherif AM et al.. 2000. Decreased synthesis and expression of TGF-beta1, beta2, and beta3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, and immunocytochemistry.. J Pathol 192(4):494-501 PMID: 11113867
- 7. Chiou WF et al.. 2014. (+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation.. PLoS One 9(2):e89159 PMID: 24558484
- 8. Liu FL et al.. 2010. GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes.. Exp Mol Pathol 88(1):163-70 PMID: 19818765
